AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Summit Therapeutics PLC (NASDAQ:SMMT)
18.2801 USD
+1.300 7.657%Sponsored Reports
Loading...
| Previous Close (in USD) | 16.98 |
|---|---|
| Change | +1.300 7.657% |
| 52 W H/L (in USD) | 5.390/1.520 |
| EBITDA (in USD) | -114.75M |
| PE Ratio | 6.87 |
| Volume | 1419889 |
| Diluted Eps TTM | 0.38 |
| Total Assets (in USD) | 202.949M |
|---|---|
| Total Liabilities (in USD) | 125.257M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 71.425M |
| Market Cap (in USD) | 1,832.168 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.705M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Employees: 105
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Robert W. Duggan | CEO & Exec. Chairman | 1944 |
| 2. | Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA | Co-CEO, Pres & Director | 1970 |
| 3. | Dr. Urte Gayko Ph.D. | Head of Regulatory Affairs, Quality Assurance & Safety and Director | 1971 |
| 4. | Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 |
| 5. | Mr. Ankur Dhingra | Chief Financial Officer | 1976 |
| 6. | Ms. Michelle Avery | Director of Investor Relations | NA |
| 7. | Dr. Elaine Carla Stracker J.D., Ph.D. | Head of Compliance? & Gen. Counsel | 1961 |
| 8. | Mr. Campbell Hair | Head of HR? | NA |
| 9. | Dr. Anne Heatherington | Head of Clinical Devel. and Quantitative Sciences | NA |
| 10. | Ms. Divya Chari | Head of Global Clinical Operations | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-2.260 2.133% | 104.27 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-1.680 1.573% | 108.27 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-55.695 12.446% | 391 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-4.445 0.622% | 711 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-01-2023 | 31-01-2022 | 31-01-2021 | 31-01-2020 | 31-01-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -78.782M | -88.602M | -52.91M | 4.994M | 6.598M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -74.381M | -86.147M | -52.697M | 4.994M | 9.872M |
| Selling General Administrative | 26.7M | 23.611M | 19.232M | - | 16.187M |
| Gross Profit | 0.704M | 1.809M | 0.86M | 43.012M | 56.388M |
| Reconciled Depreciation | 2.514M | 2.455M | 2.003M | - | 1.493M |
| Ebit | -72.089M | -88.641M | -53.193M | -25.556M | 12.381M |
| Ebitda | -60.803M | -86.186M | -51.475M | 15.156M | 13.874M |
| Depreciation And Amortization | 11.286M | 2.455M | 1.718M | 0.524M | 1.493M |
| Operating Income | -72.089M | -86.186M | -53.193M | 15.156M | 12.381M |
| Other Operating Expenses | 64.283M | 87.995M | 53.194M | -39.182M | 47.688M |
| Interest Expense | 4.401M | 0.281M | 0.255M | 0M | 0.556M |
| Tax Provision | - | 0M | -0.213M | - | -3.274M |
| Interest Income | - | 0M | 0.004M | - | 0.005M |
| Net Interest Income | -4.401M | -0.281M | -0.251M | - | 3.101M |
| Income Tax Expense | -4.401M | -2.455M | -0.213M | -3.844M | -3.274M |
| Total Revenue | 0.704M | 1.809M | 0.86M | 43.012M | 56.413M |
| Total Operating Expenses | 64.283M | 87.995M | 53.194M | -39.182M | 47.688M |
| Cost Of Revenue | - | - | - | - | 0.025M |
| Total Other Income Expense Net | -6.693M | -2.416M | 0.283M | -10.162M | -5.783M |
| Net Income From Continuing Ops | -78.782M | -88.602M | -52.697M | - | 9.872M |
| Net Income Applicable To Common Shares | -78.782M | -88.602M | -52.697M | -24.035M | 7.527M |
Balance Sheet
(Currency in USD)| Breakdown | 31-01-2024 | 31-01-2023 | 31-01-2022 | 31-01-2021 | 31-01-2020 |
|---|---|---|---|---|---|
| Total Assets | 202.949M | 664.168M | 113.374M | 102.498M | 24.439M |
| Intangible Assets | - | - | 10.399M | 11.515M | 10.604M |
| Other Current Assets | 0.181M | 0.486M | 1.201M | 1.523M | 5.8M |
| Total Liab | 125.257M | 537.514M | 30.09M | 23.045M | -18.098M |
| Total Stockholder Equity | 77.692M | 126.654M | 83.284M | 79.453M | 42.537M |
| Other Current Liab | 0.717M | 16.967M | 12.219M | 4.99M | 1.494M |
| Common Stock | 7.017M | 2.11M | 0.98M | 0.826M | 3.359M |
| Capital Stock | 7.017M | 2.11M | 0.98M | 0.826M | - |
| Retained Earnings | -993.258M | -378.33M | -299.548M | -214.74M | -97.619M |
| Good Will | 1.893M | 1.798M | 2.009M | 2.03M | 1.814M |
| Other Assets | - | 0.577M | 25.521M | - | -16.377M |
| Cash | 71.425M | 348.607M | 71.791M | 66.417M | 26.858M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 20.405M | 38.782M | 25.623M | 19.89M | -1.836M |
| Current Deferred Revenue | 14.212M | - | 7.939M | 8.37M | -0.831M |
| Net Debt | 34.674M | 170.156M | -69.009M | -65.952M | -27.863M |
| Short Term Debt | 2.809M | 21.46M | 1.091M | 0.39M | -1.005M |
| Short Long Term Debt | - | 19.77M | - | - | - |
| Short Long Term Debt Total | 106.099M | 518.763M | 2.782M | 0.465M | -1.005M |
| Other Stockholder Equity | 1066.381M | 504.767M | 384.049M | 293.367M | 42.537M |
| Property Plant Equipment | - | 5.081M | 3.484M | 1.279M | 1.167M |
| Total Current Assets | 189.712M | 656.712M | 97.312M | 66.417M | 26.858M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 114.817M | - | - | - | - |
| Net Receivables | 0.848M | 6.115M | 17.159M | 10.187M | 5.13M |
| Long Term Debt | 100M | 494.54M | - | - | - |
| Inventory | 2.441M | 301.504M | 7.161M | -11.71M | - |
| Accounts Payable | 2.667M | 0.355M | 4.374M | 6.14M | 3.389M |
| Accumulated Other Comprehensive Income | -2.448M | -1.893M | -2.197M | -3.794M | - |
| Non Currrent Assets Other | 5.281M | 0.577M | 0.17M | 21.257M | - |
| Non Current Assets Total | 13.237M | 7.456M | 16.062M | 36.081M | 13.958M |
| Capital Lease Obligations | 6.099M | 4.453M | 2.782M | 0.465M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-01-2023 | 31-01-2022 | 31-01-2021 | 31-01-2020 | 31-01-2019 |
|---|---|---|---|---|---|
| Investments | -0.624M | -0.306M | -0.421M | - | -0.411M |
| Total Cashflows From Investing Activities | -0.624M | -0.306M | -0.421M | -0.287M | -0.313M |
| Total Cash From Financing Activities | 620.244M | 77.916M | 50.551M | 33.113M | 43.855M |
| Net Income | -78.782M | -88.602M | -52.697M | -25.556M | 6.598M |
| Change In Cash | 576.816M | 5.374M | 2.575M | 6.756M | 8.861M |
| Begin Period Cash Flow | 71.791M | 66.417M | 63.842M | 20.102M | 26.365M |
| End Period Cash Flow | 648.607M | 71.791M | 66.417M | 26.858M | 35.226M |
| Total Cash From Operating Activities | -41.582M | -72.587M | -48.111M | -26.663M | -35.143M |
| Depreciation | 2.514M | 2.455M | 2.003M | 1.473M | 1.493M |
| Other Cashflows From Investing Activities | - | - | -0.421M | 0.004M | 0.004M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | 3.595M | -6.607M | - | 0M |
| Sale Purchase Of Stock | - | - | - | - | 0M |
| Other Cashflows From Financing Activities | 545.244M | 112.916M | 0.551M | 33.113M | -1.588M |
| Capital Expenditures | 0.624M | 0.306M | 0.421M | 0.119M | 0.164M |
| Change In Working Capital | 8.616M | -0.067M | 0.619M | 4.375M | -51.181M |
| Other Non Cash Items | 14.122M | 0.497M | -0.385M | -28.136M | 1.726M |
| Free Cash Flow | -42.206M | -72.893M | -48.532M | -26.782M | -35.307M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 7 months ago | 5048900 |
| 2. | Fidelity Select Biotechnology | 8 months ago | 4354329 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 3591598 |
| 4. | iShares Russell 2000 ETF | 7 months ago | 2690215 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 1882444 |
| 6. | Fidelity Small Cap Index | 9 months ago | 1185193 |
| 7. | Fidelity Select Health Care | 8 months ago | 1000000 |
| 8. | iShares Russell 2000 Growth ETF | 7 months ago | 975789 |
| 9. | Fidelity Extended Market Index | 8 months ago | 719642 |
| 10. | State St Russell Sm/Mid Cp® Indx NL Cl C | 7 months ago | 713485 |
| 11. | Fidelity Growth Compy Commingled Pl O | 8 months ago | 691500 |
| 12. | iShares Biotechnology ETF | 7 months ago | 605784 |
| 13. | Fidelity Advisor Health Care I | 8 months ago | 600000 |
| 14. | Schwab US Small-Cap ETF™ | 7 months ago | 595901 |
| 15. | Fidelity Growth Company Fund | 8 months ago | 526499 |
| 16. | Direxion Daily S&P Biotech Bull 3X ETF | 7 months ago | 508069 |
| 17. | ALPS Medical Breakthroughs ETF | 7 months ago | 491087 |
| 18. | Vanguard Health Care ETF | 7 months ago | 472726 |
| 19. | Vanguard Russell 2000 ETF | 7 months ago | 432710 |
| 20. | State St Russell Sm Cap® Indx SL Cl I | 7 months ago | 422700 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 11 months ago | 9759383 |
| 2. | Vanguard Group Inc | 8 months ago | 7269243 |
| 3. | Geode Capital Management, LLC | 11 months ago | 3085666 |
| 4. | State Street Corporation | 11 months ago | 2456168 |
| 5. | Northern Trust Corp | 11 months ago | 1108089 |
| 6. | Charles Schwab Investment Management Inc | 8 months ago | 1016545 |
| 7. | Morgan Stanley - Brokerage Accounts | 11 months ago | 704272 |
| 8. | Rafferty Asset Management, LLC | 8 months ago | 650286 |
| 9. | Steward Partners Investment Advisory, LLC | 11 months ago | 600000 |
| 10. | Nuveen Asset Management, LLC | 11 months ago | 565624 |
| 11. | Citigroup Inc | 8 months ago | 559006 |
| 12. | Federated Hermes Inc | 8 months ago | 551769 |
| 13. | ALPS Advisors Inc | 8 months ago | 494924 |
| 14. | Goldman Sachs Group Inc | 11 months ago | 388816 |
| 15. | Bank of New York Mellon Corp | 11 months ago | 342529 |
| 16. | Barclays PLC | 11 months ago | 318565 |
| 17. | Sectoral Asset Management Inc | 8 months ago | 315000 |
| 18. | JPMorgan Chase & Co | 11 months ago | 296205 |
| 19. | Swiss National Bank | 8 months ago | 275000 |
| 20. | Susquehanna International Group, LLP | 11 months ago | 230350 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
